Atrium Therapeutics prices USD 50 million private placement at USD 7.93 per share
Bitget2026/10/08 10:31Atrium Therapeutics priced an unregistered $50 million private placement, expected to close on or about Oct. 9, 2026. Deal includes 5,170,384 common shares at $7.93 each, plus pre-funded warrants for 1,134,930 shares at $7.929. Proceeds earmarked for lead RNA cardiology programs, other research, working capital, general corporate purposes; runway projected through 2028. Leerink Partners to lead placement agent role; Cantor, Barclays, Wells Fargo Securities to serve as placement agents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA66725) on October 08, 2026, and is solely responsible for the information contained therein.
- Atrium Therapeutics priced an unregistered $50 million private placement, expected to close on or about Oct. 9, 2026.
- Deal includes 5,170,384 common shares at $7.93 each, plus pre-funded warrants for 1,134,930 shares at $7.929.
- Proceeds earmarked for lead RNA cardiology programs, other research, working capital, general corporate purposes; runway projected through 2028.
- Leerink Partners to lead placement agent role; Cantor, Barclays, Wells Fargo Securities to serve as placement agents.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
